Amneal Pharmaceuticals, Inc.

AMRX • Drug Manufacturers - Specialty & Generic

$17.44

▼ -0.43 (-2.41%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$5.72B

Crecimiento

7.9%

Flujo de caja

4/5

Tendencia

Mostly stable

Evidencia

Flujo de caja libre positivo · 0.86Flujo de caja libre consistente · 4/5Liquidez saludable · 2.17Múltiplo de ganancias caro · 54.8Tendencia de crecimiento negativa

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 7 ago 2026, 12:40 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$17.44

Change-2.41%

Shares Out328.10M

Market Cap$5.72B

Enterprise Value$8.26B

52W Range8.01 - 19.26

Beta1.26

P/E36.31

P/S1.84

P/B173.27

P/FCF44.12

EV/Sales2.65

Price$17.44

Change-2.41%

Shares Out328.10M

Market Cap$5.72B

Enterprise Value$8.26B

52W Range8.01 - 19.26

Beta1.26

P/E36.31

P/S1.84

P/B173.27

P/FCF44.12

EV/Sales2.65

EV/EBITDA18.46

EV/FCF63.72

Earnings Yield2.75%

FCF Yield2.27%

Dividend Yield0.00%

Gross Margin37.63%

Oper. Margin14.02%

Profit Margin2.39%

Debt/Eq-38.65

Current Ratio2.17

Quick Ratio1.48

Revenue 5Y7.94%

FCF 5Y15.65%

Target$20.67

Target Upside18.52%

Target Median$21.00

Target Range16.00 - 25.00

Volume1.15M

Avg Volume1.92M

EPS Surprise0.10

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

55/100

Fortaleza financiera

Deuda, caja, estabilidad

70/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

69/100

Por qué este puntaje▼

Flujo de caja libre positivo · 0.86Flujo de caja libre consistente · 4/5Liquidez saludable · 2.17Múltiplo de ganancias caro · 54.8Tendencia de crecimiento negativa

Analyst view

Analyst sentiment and price target

AMRX

Analyst sentiment

Based on 17 analyst votes · 2026-09-05

82/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-07

Bajo

$16.00

Promedio

$19.75

Mediana

$19.00

Alto

$25.00

Resumen de la compañía

IPO: 5/7/2018

Industria: Drug Manufacturers - Specialty & Generic

P/B i: 173.27

Deuda / Patrimonio i: -38.65

Margen operativo: 14.02%

Margen neto: 2.39%

ROE i: -

ROIC: -

Salud financiera

Puntaje14 / 20

Deuda / Patrimonio: -38.65

Ratio corriente: 2.17

Ratio rápido: 1.48

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Autor Deborah M.

Transacción: 05/11/2026

VENTA

Cambio

-34,819

Precio

$12.94

Presentación

05/12/2026

Tipo

VENTA

Yanai Shlomo

Transacción: 05/07/2026

VENTA

Cambio

-34,819

Precio

Not reported

Presentación

05/08/2026

Tipo

VENTA

Yanai Shlomo

Transacción: 05/07/2026

COMPRA

Cambio

+34,819

Precio

Not reported

Presentación

05/08/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Autor Deborah M.	VENTA	-34,819	$12.94	05/11/2026	05/12/2026
Yanai Shlomo	VENTA	-34,819	Not reported	05/07/2026	05/08/2026
Yanai Shlomo	COMPRA	+34,819	Not reported	05/07/2026	05/08/2026
MEISTER PAUL M	VENTA	-48,747	Not reported	05/07/2026	05/08/2026
MEISTER PAUL M	COMPRA	+48,747	Not reported	05/07/2026	05/08/2026
Nark Ted C	VENTA	-34,819	Not reported	05/07/2026	05/08/2026
Nark Ted C	COMPRA	+34,819	Not reported	05/07/2026	05/08/2026
Kiely John	VENTA	-34,819	Not reported	05/07/2026	05/08/2026
Kiely John	COMPRA	+34,819	Not reported	05/07/2026	05/08/2026
Patel Gautam	VENTA	-34,819	Not reported	05/07/2026	05/08/2026
Patel Gautam	COMPRA	+34,819	Not reported	05/07/2026	05/08/2026
George Jeffrey P.	VENTA	-34,819	Not reported	05/07/2026	05/08/2026
George Jeffrey P.	COMPRA	+34,819	Not reported	05/07/2026	05/08/2026
Autor Deborah M.	VENTA	-34,819	Not reported	05/07/2026	05/08/2026
Autor Deborah M.	COMPRA	+34,819	Not reported	05/07/2026	05/08/2026
BUCHI J KEVIN	VENTA	-34,819	Not reported	05/07/2026	05/08/2026
BUCHI J KEVIN	COMPRA	+34,819	Not reported	05/07/2026	05/08/2026
Yanai Shlomo	COMPRA	+19,824	Not reported	05/06/2026	05/08/2026
MEISTER PAUL M	COMPRA	+30,837	Not reported	05/06/2026	05/08/2026
Nark Ted C	COMPRA	+19,824	Not reported	05/06/2026	05/08/2026

Sobre la compañía

Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

Fuente - Link

Competidores

BHC DYN INDV LNTH MIRM NVST PRGO SLNO SUPN TLX

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low

COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.

Zacks Investment Research

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

Zacks Investment Research

STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)---- $AMRX #AMRX--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company's current shareholders.The investigation seeks to determine whether Amneal or the company's officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional informat.

Business Wire

5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns

Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.

Zacks Investment Research

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.

Zacks Investment Research

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-07	0.17	0.27	0.1
2026-02-27	0.18	0.21	0.03
2025-10-30	0.13	0.17	0.04
2025-08-05	0.18	0.25	0.07
2025-05-02	0.15	0.21	0.06
2025-02-28	0.15	0.12	-0.03
2024-11-08	0.13	0.16	0.03
2024-08-09	0.14	0.16	0.02
2024-05-03	0.09	0.14	0.05
2024-03-01	0.07	0.14	0.07
2023-11-07	0.12	0.19	0.07
2023-08-04	0.1	0.19	0.09